Keryx Biopharmaceuticals (KERX) Shares are Up 4.65%

Keryx Biopharmaceuticals (KERX) : Traders are bullish on Keryx Biopharmaceuticals (KERX) as it has outperformed the S&P 500 by a margin of 18.61% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.02%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.65% in the last 1 week, and is up 26.62% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Keryx Biopharmaceuticals (NASDAQ:KERX): The stock opened at $7.48 on Friday but the bulls could not build on the opening and the stock topped out at $7.51 for the day. The stock traded down to $7.34 during the day, due to lack of any buying support eventually closed down at $7.42 with a loss of -1.20% for the day. The stock had closed at $7.51 on the previous day. The total traded volume was 821,697 shares.


The stock has recorded a 20-day Moving Average of 8.24% and the 50-Day Moving Average is 18.31%. Keryx Biopharmaceuticals Inc. is up 44.08% in the last 3-month period. Year-to-Date the stock performance stands at 46.93%.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.